Contact this trialFirst, we need to learn more about you.
mTOR inhibitor
Everolimus +1 More for Pancreatic Neuroendocrine Tumors
Recruiting1 awardPhase 2
Monroe, Michigan
This study is evaluating whether a combination of everolimus and octreotide acetate with or without bevacizumab works better than everolimus and octreotide acetate with or without bevacizumab in treating patients with pancreatic neuroendocrine tumors that cannot be
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.